Department of Nuclear Medicine, Clinical Hospital Center Rijeka, Rijeka, Croatia.
Clinic for Surgery, Clinical Hospital Center Rijeka, Rijeka, Croatia.
Strahlenther Onkol. 2020 Nov;196(11):1044-1054. doi: 10.1007/s00066-020-01669-x. Epub 2020 Jul 24.
Based on the risk of locoregional recurrence (LRR), postmastectomy radiotherapy (PMRT) is recommended in T1-T2pN1 breast carcinoma (BC). We aimed to elucidate our institutional strategies underlying selection of these patients for PMRT. In the no-PMRT subset, we compared various lymph node (LN) staging systems' abilities to predict 5‑year overall and locoregional-free survival (OS/LRFS).
We retrospectively enrolled 548 women with T1-T2pN1 BC undergoing mastectomy and axillary LN dissection. Depending on PMRT delivery, the participants were divided into the PMRT and no-PMRT groups. Predictors of OS/LRFS were calculated for the no-PMRT group only. Based on Cox regression modelling, the number of positive LNs (PLN), negative LNs (NLN), LN ratio (LNR), log odds of PLN (LODDS), and modified LNR (mLNR) were modelled, each respectively, with OS model covariates (age, grade III, lymphovascular invasion [LVI], tumor size, hormone receptor [HR] status) and LRFS model covariates (age, grade III, LVI). The C‑statistic, Akaike information criterion, and likelihood ratio χ of the models were compared.
Median follow-up was 60.5 (18-82), 61 (28-82), and 60 (18-80) months for the entire cohort, PMRT, and no-PMRT group, respectively. The PMRT and no-PMRT groups had comparable OS (p = 0.235). LRFS was better (p = 0.030) in the PMRT group comprising 105 subjects (19.16%) who were younger, more likely to have a higher-grade, HR-, HER2+ tumors, more PLNs, fewer NLNs, Ki-67 ≥ 20%, LVI, and extranodal extension (p ≤ 0.001). In the no-PMRT group, LNR-based OS/LRFS models exhibited superior prognostic performance.
In early-stage BC patients undergoing mastectomies, LN dissections and no PMRT, we propose LNR-based multivariable models to predict OS/LRFS with superior accuracy.
基于局部区域复发(LRR)的风险,推荐 T1-T2pN1 乳腺癌(BC)患者行乳房切除术放疗(PMRT)。我们旨在阐明我们机构选择这些患者进行 PMRT 的策略。在不进行 PMRT 的亚组中,我们比较了各种淋巴结(LN)分期系统预测 5 年总生存(OS)和局部区域无复发生存(LRFS)的能力。
我们回顾性纳入了 548 例接受乳房切除术和腋窝淋巴结清扫术的 T1-T2pN1BC 女性患者。根据 PMRT 的应用情况,将患者分为 PMRT 组和无 PMRT 组。仅对无 PMRT 组计算 OS/LRFS 的预测因素。基于 Cox 回归模型,分别对阳性淋巴结(PLN)数、阴性淋巴结(NLN)数、淋巴结比(LNR)、对数优势比 PLN(LODDS)和改良 LNR(mLNR)进行建模,分别与 OS 模型协变量(年龄、分级 III、脉管侵犯[LVI]、肿瘤大小、激素受体[HR]状态)和 LRFS 模型协变量(年龄、分级 III、LVI)进行建模。比较模型的 C-统计量、Akaike 信息准则和似然比 χ。
全队列、PMRT 组和无 PMRT 组的中位随访时间分别为 60.5(18-82)、61(28-82)和 60(18-80)个月。PMRT 组和无 PMRT 组的 OS 无差异(p=0.235)。LRFS 在包含 105 例(19.16%)年轻患者的 PMRT 组中更好(p=0.030),这些患者更可能为高级别、HR-、HER2+肿瘤,有更多的 PLN、更少的 NLN、Ki-67≥20%、LVI 和额外的淋巴结外扩散(p≤0.001)。在无 PMRT 组中,基于 LNR 的 OS/LRFS 模型显示出更好的预后预测性能。
在接受乳房切除术、淋巴结清扫术和无 PMRT 的早期 BC 患者中,我们提出基于 LNR 的多变量模型来预测 OS/LRFS,其准确性更高。